---
title: "SUNSHINE PHARMA plans to implement full circulation of H shares"
description: "SUNSHINE PHARMA announced a proposal to implement full circulation of H shares, involving the conversion of 251 million domestic shares, accounting for 43.59% of the company's total share capital"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/255345770.md"
published_at: "2025-08-31T09:19:32.000Z"
---

# SUNSHINE PHARMA plans to implement full circulation of H shares

> SUNSHINE PHARMA announced a proposal to implement full circulation of H shares, involving the conversion of 251 million domestic shares, accounting for 43.59% of the company's total share capital

SUNSHINE PHARMA (06887.HK) announced the proposal to implement full circulation of H shares, involving the conversion of 251 million domestic shares, accounting for 43.59% of the company's total share capital

### Related Stocks

- [06887.HK - SUNSHINE PHARMA](https://longbridge.com/en/quote/06887.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Olympics-Figure skating-U.S. Figure Skating won't appeal Chock and Bates ice dance results | U.S. Figure Skating will not appeal the ice dance results from the Milano Cortina Games, where Madison Chock and Evan Ba | [Link](https://longbridge.com/en/news/276012027.md) |
| Codeifai Enters AI-Backed Quantum Security Market | Codeifai Ltd :CODEIFAI ENTERS AI-BACKED QUANTUM SECURITY MARKETCOMPLETION OF ACQUISITION OF ANTENNATRANSFER.IOTOTAL CONS | [Link](https://longbridge.com/en/news/276015719.md) |
| Olympics-Curling-As double touching drama continues at Games, curlers are open to video review | As controversy over double touching stones continues in curling at the Winter Olympics, players express openness to vide | [Link](https://longbridge.com/en/news/276010244.md) |
| ICICI Securities Reaffirms Their Buy Rating on Aurobindo Pharma Ltd (AUROPHARMA) | In a report released today, from ICICI Securities maintained a Buy rating on Aurobindo Pharma Ltd, with a price target o | [Link](https://longbridge.com/en/news/276010991.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/en/news/276016059.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.